{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:15Z","timestamp":1792515675664,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013077","name":"National Science and Technology Planning Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejso.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T02:16:24Z","timestamp":1567649784000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Aoshuang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghe","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force","volume":"319","author":"Henderson","year":"2018","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib2","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejso.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejso.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2019.09.002_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group","volume":"83","year":"2000","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2019.09.002_bib11","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Satagopan","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","article-title":"Ovarian cancer screening--current status, future directions","volume":"132","author":"Menon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","article-title":"Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers","volume":"23","author":"Kramer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1055-9965.EPI-06-0829","article-title":"Age at menarche and menopause and breast cancer risk in the International BRCA1\/2 Carrier Cohort Study","volume":"16","author":"Chang-Claude","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejso.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/95.14.1072","article-title":"Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study","volume":"95","author":"Rutter","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2008.06.003","article-title":"Hereditary ovarian cancer","volume":"69","author":"Russo","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejso.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.1995.03520300065039","article-title":"NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer","volume":"273","year":"1995","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","article-title":"Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy","volume":"18","author":"Lu","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ajog.2006.03.006","article-title":"Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy","volume":"194","author":"Lamb","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejso.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","article-title":"Microscopic and early-stage ovarian cancers in BRCA1\/2 mutation carriers: building a model for early BRCA-associated tumorigenesis","volume":"4","author":"Yates","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ejso.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol","volume":"21","author":"Powell","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.12.009","article-title":"Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","volume":"132","author":"Conner","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jmig.2017.03.001","article-title":"The role of routine peritoneal and omental biopsies at risk-reducing salpingo-oophorectomy","volume":"24","author":"Miller","year":"2017","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.ejso.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ygyno.2018.02.014","article-title":"Characteristics of african American women at high-risk for ovarian cancer in the southeast: results from a gynecologic cancer risk assessment clinic","volume":"149","author":"Barrington","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/his.13503","article-title":"Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes","volume":"73","author":"Wong","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2019.09.002_bib38","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ejhg.2009.60","article-title":"Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk","volume":"17","author":"Evans","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1471-0528.2011.02920.x","article-title":"Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status","volume":"118","author":"Manchanda","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.ejso.2019.09.002_bib40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/IGC.0b013e3181a1b5dc","article-title":"High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy","volume":"19","author":"Hirst","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib41","first-page":"199","article-title":"Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers","volume":"21","author":"Primas","year":"2012","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ejso.2019.09.002_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/IGC.0000000000000954","article-title":"Challenging salpingectomy as a risk-reducing measure for ovarian cancer: histopathological analysis of the tubo-ovarian interface in women undergoing risk-reducing salpingo-oophorectomy","volume":"27","author":"Ayres","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00000478-200110000-00009","article-title":"Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status","volume":"25","author":"Colgan","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2010.12.333","article-title":"Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection","volume":"120","author":"McAlpine","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib46","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.22603","article-title":"Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation","volume":"109","author":"Laki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib47","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/IGC.0b013e318257b936","article-title":"Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population","volume":"22","author":"Bacha","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib48","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11845-017-1717-6","article-title":"Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes","volume":"187","author":"Thompson","year":"2018","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.ejso.2019.09.002_bib49","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/01.pas.0000202161.80739.ac","article-title":"Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature","volume":"30","author":"Carcangiu","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jmig.2017.04.017","article-title":"Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience","volume":"24","author":"Bogani","year":"2017","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.ejso.2019.09.002_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/IGC.0000000000000624","article-title":"Clinical and pathological characteristics of incidental diagnostic early occult malignancy after risk-reducing salpingo-oophorectomy in BRCA mutation carriers","volume":"26","author":"Lavie","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib52","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","article-title":"Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up","volume":"90","author":"Olivier","year":"2004","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2019.09.002_bib53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2012.06.015","article-title":"Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls","volume":"127","author":"Mingels","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clon.2018.03.036","article-title":"Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review","volume":"30","author":"Van der Hoeven","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00432-015-2051-x","article-title":"Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea","volume":"142","author":"Kim","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib57","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2017.28.e3","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers","volume":"28","author":"Lee","year":"2017","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12094-018-1865-9","article-title":"Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study","volume":"20","author":"Minig","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib59","first-page":"183","article-title":"Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia","volume":"16","author":"Leunen","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib60","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","article-title":"The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients","volume":"27","author":"Wu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib61","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00432-009-0607-3","article-title":"BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients","volume":"135","author":"Lim","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.29707","article-title":"BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/159f0ba3-5a24-4de9-99be-1cd6d5037760","article-title":"Prevalence of BRCA1 mutations in familial and sporadic Greek ovarian cancer cases","volume":"8","author":"Stavropoulou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2019.09.002_bib64","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ijc.11338","article-title":"Hereditary ovarian cancer in Poland","volume":"106","author":"Menkiszak","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2014.05.002","article-title":"Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania","volume":"207","author":"Janavicius","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.ejhg.5200652","article-title":"BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients","volume":"9","author":"Sarantaus","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib67","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<737::AID-IJC21>3.0.CO;2-1","article-title":"Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary","volume":"86","author":"Van Der Looij","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib68","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1158\/1055-9965.EPI-05-0687","article-title":"Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations","volume":"15","author":"Lee","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejso.2019.09.002_bib70","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/342506","article-title":"Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan","volume":"71","author":"Liede","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.09.002_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.2000.5848","article-title":"Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients","volume":"78","author":"Tobias","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib73","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib74","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2019.09.002_bib75","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","article-title":"BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia","volume":"124","author":"Rodriguez","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib77","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-0004.1999.550504.x","article-title":"Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history","volume":"55","author":"Tonin","year":"1999","journal-title":"Clin Genet"},{"key":"10.1016\/j.ejso.2019.09.002_bib78","first-page":"3412","article-title":"A\u00a0survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer","volume":"97","author":"Li","year":"2017","journal-title":"Zhonghua Yixue Zazhi"},{"key":"10.1016\/j.ejso.2019.09.002_bib79","first-page":"49","article-title":"Questionnaire survey on the attitude to genetic counseling and testing for gynecologic oncology by Chinese healthcare providers","volume":"27","author":"Qiu","year":"2018","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ejso.2019.09.002_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","article-title":"Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review","volume":"61","author":"Arts-de Jong","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib81","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s10897-017-0108-5","article-title":"Universal BRCA1\/BRCA2 testing for ovarian cancer patients is welcomed, but with care: how women and staff contextualize experiences of expanded access","volume":"26","author":"Shipman","year":"2017","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.ejso.2019.09.002_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00004347-199707000-00001","article-title":"Tumors of the fimbriated end of the fallopian tube: a clinicopathologic analysis of 20 cases, including nine carcinomas","volume":"16","author":"Alvarado-Cabrero","year":"1997","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib84","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejso.2019.09.002_bib85","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib86","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/PAS.0b013e318282da7f","article-title":"Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis","volume":"37","author":"Bijron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2019.09.002_bib87","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2015.09.018","article-title":"Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review","volume":"139","author":"Patrono","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib88","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/IGC.0000000000001041","article-title":"European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery","volume":"27","author":"Querleu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib89","first-page":"50","article-title":"Development of peritoneal carcinoma in women diagnosed with serous tubal intraepithelial carcinoma (STIC) following risk-reducing salpingo-oophorectomy (RRSO)","volume":"12","author":"Stanciu","year":"2019","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.ejso.2019.09.002_bib90","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib91","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from gynecologic oncology group trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib92","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers","volume":"124","author":"Domchek","year":"2010","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejso.2019.09.002_bib93","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.09.002_bib94","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib95","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2019.09.002_bib96","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for ovarian cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2019.09.002_bib97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamaoncol.2017.4211","article-title":"Estimating cost-effectiveness of a multimodal ovarian cancer screening program in the United States: secondary analysis of the UK collaborative trial of ovarian cancer screening (UKCTOCS)","volume":"4","author":"Moss","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319306626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319306626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:32:25Z","timestamp":1760059945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319306626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0748798319306626"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.09.002","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}